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Red Blood Cell Precursor Mass as an Independent Determinant of Serum
Erythropoietin Level
By Mario Cazzola, Roberta Guarnone, Paola Cerani, Esther Centenara, Andrea Rovati, and Yves Beguin
Serum erythropoietin (sEpo) concentration is primarily re-
lated to the rate of renal production and, under the stimulus
of hypoxia, increases exponentially as hemoglobin (Hb)
decreases. Additional factors, however, appear to influence
sEpo, and in this work, we performed studies to evaluate the
role of the red blood cell precursor mass. We first compared
the relationship of sEpo with Hb in patients with low versus
high erythroid activity. The first group included 27 patients
with erythroid aplasia or hypoplasia having serum transfer-
rin receptor (sTfR) levels F 3 mg/L (erythroid activity F 0.6
times normal), while the second one included 28 patients
with b-thalassemia intermedia having sTfR levels G 10 mg/L
(erythroid activity G 2 times normal). There was no differ-
ence between the two groups with respect to Hb (8.3 6 1.6 v
8.0 6 1.3 g/dL, P G .05), but sEpo levels were notably higher
in patients with low erythroid activity (1,601 6 1,542 v 235 6
143 mU/mL, P F .001). In fact, multivariate analysis of
variance (ANOVA) showed that, at any given Hb level, sEpo
was higher in patients with low erythroid activity (P F
.0001). Twenty patients undergoing allogeneic or autologous
bone marrow transplantation (BMT) were then investigated.
A marked increase in sEpo was seen in all cases at the time of
marrow aplasia, disproportionately high when compared
with the small decrease in Hb level. Sequential studies were
also performed in five patients with iron deficiency anemia
undergoing intravenous (IV) iron therapy. Within 24 to 72
hours after starting iron treatment, marked decreases in
sEpo (up to one log magnitude) were found before any
change in Hb level. Similar observations were made in
patients with megaloblastic anemia and in a case of pure red
blood cell aplasia. These findings point to an inverse relation-
ship between red blood cell precursor mass and sEpo: at any
given Hb level, the higher the number of red blood cell
precursors, the lower the sEpo concentration. The most
likely explanation for this is that sEpo levels are regulated
not only by the rate of renal production, but also by the rate
of utilization by erythroid cells.
r 1998 by The American Society of Hematology.
IN ADULT HUMANS, erythropoietin (Epo) is primarilymade by a single organ, the kidney, outside the bone
marrow (BM) and participates in a classic negative feedback
control system.1,2 Hypoxia is the fundamental physiologic
stimulus that causes a rapid increase in renal production of
erythropoietin through an exponential increase in the number of
erythropoietin-producing cells. It is generally accepted that
serum Epo (sEpo) concentration is directly related to the rate of
renal production. Serum erythropoietin levels are in the range of
5 to 30 mU/mL in normal individuals and increase exponen-
tially as hemoglobin (Hb) or hematocrit (Hct) decreases, unless
there is a blunted renal production.3
With the availability of commercial immunoassays for sEpo,
assessment of endogenous Epo production has become a routine
diagnostic procedure. Serum Epo is evaluated in relation to the
degree of anemia, and the definition of defective Epo produc-
tion relies on a low sEpo in comparison to reference patients
with similar Hct (or Hb).3 In the individual patient, the
adequacy of endogenous Epo production can be easily assessed
through the observed/predicted log (sEpo) ratio (O/P ratio).4
The O/P ratio is below 1 if the observed value is lower than the
predicted one; in reference subjects, the 95% confidence
interval ranged from 0.80 to 1.22.4
With the only exceptions of prematurity and renal failure,
determination of sEpo is mandatory in all anemic patients for
deciding treatment with recombinant human Epo (rHuEpo).5 In
fact, it is mainly in patients in whom endogenous Epo levels are
inappropriately low for the degree of anemia that administration
of rHuEpo can be effective in increasing red blood cell
production. In particular, several reports point to the use of a
sEpo threshold of # 100 mU/mL for predicting response to
rHuEpo in patients with Hb levels , 10 g/dL.6,7
Although tissue hypoxia is the fundamental physiologic
stimulus that increases renal secretion, a number of clinical
observations suggest that other factors might be involved in the
regulation of Epo production and/or may influence serum
concentration. Abnormally high Epo levels have been reported
in patients with aplastic anemia,8,9 and dramatic changes in
serum levels have been described after chemotherapy10,11 and
during vitamin B12 or iron replacement therapy.12,13 These
findings point to an inverse relationship between red blood cell
precursor mass and sEpo levels.14 In this study, we performed
studies to evaluate whether the red blood cell precursor mass is
an independent determinant of sEpo concentration.
MATERIALS AND METHODS
Patients. This study was designed to evaluate whether the red
blood cell precursor mass can directly and independently influence
sEpo levels. Therefore, we planned to study: (1) sEpo levels in patients
with low versus high erythroid activity; (2) the time course of sEpo in
patients undergoing myeloablative therapy for bone marrow transplan-
tation (BMT); and (3) the time course of sEpo in anemic patients with
iron deficiency or vitamin B12 deficiency undergoing specific replace-
ment therapy.
Anemic patients with low versus high erythroid activity. To identify
any effect of the erythroid marrow activity on sEpo concentration, we
selected two groups of anemic patients: one with defective erythroid
proliferation and decreased numbers of erythroid precursors (hypopro-
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liferative anemia), the second one with ineffective erythropoiesis and
elevated numbers of marrow immature red blood cells (proliferative
anemia). The degree of erythroid proliferation was evaluated through
the serum transferrin receptor (sTfR) level (see below). Patients with
severe aplastic anemia (n 5 11), pure red blood cell aplasia (PRCA, n 5
7), or mild hypoplastic anemia (n 5 9) having values for erythroid
proliferation below the normal range (sTfR , 3 mg/L) were included in
the hypoproliferative anemia group. Twenty-eight individuals with
b-thalassemia intermedia having sTfR levels . 10 mg/Ll were included
in the group of anemic patients with high erythroid activity.
Sequential studies in patients receiving myeloablative therapy or
conventional chemotherapy. Twenty patients undergoing allogeneic
(n 5 14) or autologous (n 5 6) BMT were investigated immediately
before undergoing myeloablative therapy and on day 0. Previous studies
on evolution of erythropoiesis and Epo after BMT15 showed that sEpo
had a peak value on day 0, while sTfR decreased sharply after
conditioning to a minimum on day 14. Therefore, for the purpose of this
study, we decided to assay sEpo and sTfR before transplant and on day
0. Similar studies were performed in five patients undergoing chemother-
apy for non-Hodgkin’s lymphoma.
Sequential studies in patients with iron deficiency anemia treated
with intravenous (IV) iron saccharate. The five patients with severe
iron deficiency anemia had a mean Hb level of 6.4 6 1.4 g/dL (range,
4.2 to 7.4 g/dL) and a mean serum ferritin of 5 6 4 µg/L (range, 2 to 10
µg/L). They received IV iron therapy (iron oxide saccharate, Ferrum
Hausman, Laboratorien Hausman, St. Gallen, Switzerland). The total
amount of iron required was calculated according to the following
formula16: total dose (mg) 5 [Hb deficit (g/dL) 3 estimated blood
volume (dL) 3 3.4] 1 500, where Hb deficit is the difference between
15 and the patient’s Hb level, blood volume is estimated according to
sex and body surface,17 3.4 is the factor converting g Hb to mg iron, and
500 is an arbitrary quantity to allow for restoration of the iron reserve.
The daily dose was 100 or 200 mg of iron saccharate: this amount was
diluted in 250 mL of normal saline and infused IV over 1 hour.
Case reports. Additional studies were performed in two patients
with megaloblastic anemia due to vitamin B12 deficiency or folic acid
deficiency and in one patient with pure red blood cell aplasia after
autologous BMT for treament of non-Hodgkin’s lymphoma.
In the treatment of megaloblastic anemia, vitamin B12 was adminis-
tered intramuscular (IM) as cyanocobalamin, 500 µg per day; folic acid
was administered IM at a dose of 15 mg per day.
The patient with PRCA was previously reported.18 He was given high
doses of rHuEpo (150 U/kg per day subcutaneously [SC], 5 days a
week) based on previous observations on the use of Epo in the treatment
of PRCA after stem cell transplantation (reviewed in our previous
report18). During treatment, sEpo was measured on Monday morning,
ie, approximately 72 hours after the last SC rHuEpo administration. In
normal individuals receiving SC rHuEpo, sEpo increases from basal
levels of 10 to 20 mU/mL to peak values of 30 to 40 mU/mL after about
12 hours and then decreases with a half-life of about 24 hours (see
review by Cazzola et al5).
Hematologic profile. Blood counts were determined with a Coulter
Counter Model S (Coulter, Hialeah, FL). Reticulocyte counts were
performed with an automated reticulocyte analyzer Sysmex R-3000
(Toa Medical Electronics GmbH, Hamburg, Germany). This system
performs reticulocyte analysis using flow cytometry, with an argon laser
as the light source. Whole blood specimens stained with a fluorescent
dye pass through a sheath flow cell, where fluorescently-labeled cells
are irradiated with a laser beam and thus produce forward scatter and
fluorescence. The scatter and fluorescence are detected as indicator of
the relative cell size and the RNA content, respectively. Reticulocyte
count is expressed both as an absolute number per µL and as a
percentage of red blood cells. Dividing the reticulocyte area of the
scattergram into three sections according to the fluorescent intensity,
reticulocytes can then be fractionated into maturity stages: HFR (high
fluorescence ratio, immature reticulocytes), MFR (middle fluorescence
ratio, intermediate reticulocytes), and LFR (low fluorescence ratio,
mature reticulocytes).
Serum erythropoietin assay. Circulating Epo levels were measured
by a commercially available radioimmunoassay (Incstar Corp, Sillwa-
ter, MN) that uses rHuEpo for tracer and standards.4 To define Epo
levels as appropriate or inappropriate for a given degree of anemia, an
exponential regression of sEpo versus Hct was determined in reference
subjects (102 normal individuals or patients with iron deficiency
anemia, hemolytic anemia, or hypoplastic anemia), and the 95%
confidence limits were defined. For Hct values #40%, the regression
equation was: log(epo) 5 3.42 2 (0.056 3 Hct). For Hct values .40%,
the regression equation was: log(epo) 5 1.31 2 (0.003 3 Hct). Based
on these equations, the observed/predicted log(epo) ratio (O/P ratio)
was derived for each sample. The mean O/P ratio in reference subjects
was 1.01 6 0.11 (95% confidence interval, 0.80 to 1.22).
Measurement of sTfR. The amount of circulating transferrin recep-
tor was estimated by an enzyme-linked polyclonal antibody assay, using
purified placental receptor-transferrin complexes as a reference stan-
dard and rabbit antibodies as described in detail elsewhere.4 The mean
sTfR level in 165 normal control subjects was 5.0 6 1.1 mg/L, with a
normal range from 3 to 7 mg/L.
Data analysis and presentation. Data were stored, analyzed, and
reported with the packages STATISTICA/Mac (StatSoft, Tulsa, OK),
Exstatix (Select Micro Systems Inc, Yorktown Heights, NY), and
DeltaGraph Pro 3 (DeltaPoint Inc, Monterey, CA), all run on a
Macintosh Quadra 800 (Apple Computer Inc, Cupertino, CA) personal
computer. Results were expressed as mean 6 1 standard deviation (SD)
unless otherwise stated. The Student’s t test and/or the F test (one-way
analysis of variance [ANOVA]) were used to evaluate the probability of
significant differences between groups. Multivariate ANOVA was used
to show any significant difference in the regression of serum sEpo to Hb
level in different groups. P values less than .05 were considered
statistically significant.
As discussed below, the number of erythroid cells in the BM may
directly influence the Epo clearance: the higher the erythroid activity,
the lower sEpo level. To account for this effect of erythroid activity on
sEpo levels, the following correction was made:
Corrected sEPo (mU/mL) 5 measured sEPo (mU/mL) 3
ln sTfr(mg/L)
ln 5 (mg/L)
where 5 mg/L is the mean normal value for sTfR, taken as a measure of
erythroid activity. For several reasons, including the impossibility of
distinguishing between erythroid and nonerythroid TfR at the lowest
sTfR levels, an additional empirical correction was introduced: the
minimum value for ln sTfR was set to 0.2. Any time the calculated value
was , 0.2, it was changed to 0.2.
RESULTS
Serum Epo in anemic patients with low versus high erythroid
activity. As reported in Table 1, there was no significant
difference with respect to Hb level (Student’s t test 5 0.97, P $
.05) between the 27 patients with low erythroid activity
Table 1. Hb Level, sTfR, and sEpo in Anemic Patients With Low
Erythroid Activity (Hypoproliferative Anemia) Versus Anemic
























Normal range 12-16 (females) 3.0-7.0 5-30
13.5-17.5 (males)
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(hypoproliferative anemia, sTfR , 3 mg/L) and the 28 individu-
als with b-thalassemia intermedia and high erythroid activity
(sTfR . 10 mg). By contrast, sEpo levels were about one log
higher in patients with hypoproliferative anemia (Student’s t
test 5 4.67, P , .001).
Figure 1A displays the relationship of sEpo to Hb observed in
the two groups of patients. A significant inverse relationship
between Hb and sEpo was found in both patient populations
(P , .001 in both groups). However, multivariate ANOVA
showed that at any given Hb level, sEpo was higher in patients
with low versus high erythroid activity (the multivariate tests
Rao’s R and Pillai-Bartlett Trace V were both significant at P ,
.0001).
Assuming that the erythroid cells in the BM directly influ-
ence the Epo clearance rate, we made an empirical correction to
remove the effect of variation in erythroid activity on sEpo
levels using the formula reported in Materials and Methods.
As shown in Fig 1B, when we reanalyzed the data of Fig 1A
using the corrected sEpo instead of the measured sEpo levels, a
substantial part of the variation previously observed was
abolished. In fact, whereas only 15.8% of the variation in sEpo
was explained by variations in Hb level (Fig 1A), these latter
variations in Hb level explained 37.5% of the variation in
corrected sEpo. In particular, there was no difference (P . .05)
between corrected sEpo levels calculated in patients with
thalassemia intermedia having high erythroid activity and those
calculated in patients with low erythroid activity.
Sequential studies in patients receiving myeloablative therapy
or conventional chemotherapy. Twenty patients undergoing
allogeneic or autologous BMT were investigated immediately
before undergoing myeloablative therapy and on day 0 (Table 2
and Fig 2). Conditioning regimen markedly reduced erythroid
activity as shown by the sharp decrease in sTfR (t 5 10.40, P ,
.001). Day 0 values for the circulating receptor were compa-
rable with those of patients with aplastica anemia or PRCA
(Table 1).
There was also a mild, although significant decrease in Hb
level (t 5 2.93, P , .05). However, the marked increment in
sEpo (t 5 6.66, P , .001) appeared to be disproportionately
high when compared with the mild decrease in Hb level (Fig 2).
We therefore calculated for each patient the day-0 sEpo
concentration expected (or predicted) on the basis of the actual
Hb level. As displayed in Fig 2, the predicted day-0 sEpo was
significantly lower than the observed one (81 6 45 mU/mL v
254 6 141 mU/mL, t 5 6.86, P , .001), indicating that
factor(s) other than Hb level contributed to the elevation in
circulating Epo level.
Similar findings were observed in five patients with non-
Hodgkin’s lymphoma undergoing conventional chemotherapy
(Fig 3). A marked increase in serum Epo was seen in all cases
after 8 days, before any significant decrease in Hb was
observed; this was associated with a parallel decrease in sTfR.
Fig 1. Relationship of sEpo to Hb observed in 27 patients with
hypoproliferative anemia having erythroid activity F0.6 times normal
(X) versus 28 patients with b-thalassemia intermedia having ery-
throid activity G2 times normal (W). (A) Relationship of measured
sEpo to Hb level. Multivariate ANOVA showed that, at any given Hb
level, sEpo was higher in patients with low versus those with high
erythroid activity (P F .0001). (B) Relationship of corrected sEpo to Hb
level. Data are those of (A), but corrected sEpo levels have been used
instead of the measured ones. Multivariate ANOVA showed no
significant difference between the relationship in patients with low
erythroid activity and that in subjects with high erythroid activity
(P G .05).
Table 2. Hb, sTfR, and sEpo in 20 Patients Undergoing Allogeneic








Pretransplant 9.1 6 1.2 6.0 6 1.6 66 6 37
Day 0 8.6 6 1.2 2.1 6 0.5 254 6 141
Fig 2. Time course of Hb level, sEpo, and circulating transferrin
receptor in 20 patients undergoing BMT. Data are mean values 6 1
SD. Observed values before myeloablative therapy and those on day
0 are shown. Predicted sEpo values were calculated on the basis of
the patient’s Hct using the equation derived from regression analysis
as previously described.4
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Sequential studies in patients with iron deficiency anemia
treated with IV iron saccharate. Five patients with severe iron
deficiency anemia (mean Hb, 6.4 6 1.4 g/dL) were studied
immediately before and during IV iron therapy. Data of these
sequential studies are despicted in Fig 4. Within 24 to 72 hours
after starting iron treatment, marked decreases in sEpo were
observed (up to one log magnitude) before any change in Hb
level.
Because both the expression of transferrin receptors on
erythroid cells and the soluble receptor level are influenced by
the body iron status, the measurement of sTfR could not be used
in these patients to evaluate the erythroid activity. However, in
one patient, we were able to monitor the reticulocyte response
to IV iron. Figure 5 shows that the reticulocyte count and, in
particular, the percentage of immature reticulocytes (HFR),
increased sharply after starting IV iron, and this was paralleled
by a mirror decrease in sEpo.
Case reports: megaloblastic anemia and PRCA. Two pa-
tients with megaloblastic anemia were studied (Figs 6 and 7). In
both cases, replacement therapy with vitamin B12 or folate
induced a sharp decrease in sEpo in the first few days before any
change in Hb level. Such decreases were paralleled by increases
in sTfR, and in one case (Fig 7), also of immature reticulocytes
(HFR), indicating that ineffective erythropoiesis was replaced
by effective erythropoiesis with a subsequent expansion of the
red blood cell precursor mass.
Of particular interest was the patient with PRCA after
peripheral stem cell transplantation (Fig 8). His sTfR was 0.4
mg/L, indicating the complete absence of any erythroid activity:
this amount of TfR, in fact, is contributed by nonerythroid
tissues. As previously reported,18 this patient responded to
rHuEpo therapy despite the elevated sEpo (2820 mU/mL). For 4
weeks, there was no increase in Hb level: however, sTfR started
to increase after 2 weeks, and there was a parallel decrease in
sEpo despite exogenous Epo administration, suggesting in-
creased use by an expanding erythroid precursor mass.
DISCUSSION
Renal Epo production is typically regulated by a transcrip-
tional feedback mechanism where hypoxia plays a crucial
role.19,20 However, a number of additional pathophysiopatho-
logic factors, including inflammatory cytokines21 and plasma
viscosity,22 may independently affect the renal response to
hypoxia. Epo catabolism is largely unknown and it is not clear
whether sEpo levels are determined only by the production rate
or rather reflect a balance between this and consumption by
erythroid cell use.
The observation that serum Epo levels in aplastic anemia are
higher than those in iron deficiency anemia8,9 suggests that use
Fig 3. Time course of Hb level, sEpo, and circulating transferrin
receptor in five patients with non-Hodgkin’s lymphoma undergoing
conventional chemotherapy (CHOP regimen). Data are mean
values 6 1 SEM. One way ANOVA showed that Hb level did not
change significantly during the observation period (P G .05), whereas
both the decrease in circulating transferrin receptor (sTfR, F 5 6.02,
P F .01) and the mirror increase in sEpo (F 5 14.54, P F .001) were
found to be significant changes.
Fig 4. Time course of Hb level and sEpo in five patients with iron
deficiency anemia treated with IV iron saccharate from day 0. Data
are mean values 6 SEM. Within 48 hours, sEpo fell from 1,049 6 772
mU/mL to 485 6 567 mU/mL (P F .01), whereas Hb level did not
change significantly (6.4 6 1.4 v 6.4 6 1.2, P G .057).
2142 CAZZOLA ET AL
 For personal use only. by Yves Beguin on February 4, 2009. www.bloodjournal.orgFrom 
by erythroid precursors may be an important factor in determin-
ing serum concentrations. Unexpectedly low sEpo levels have
been previously found in patients with refractory anemia,23
sickle cell anemia,24 thalassemia,25 and megaloblastic anemia26
indicating that erythroid hyperplasia may involve a faster
clearance of Epo.
In the initial part of this study, we have clearly shown that the
sEpo level in aplastic anemia (erythroid activity , 0.6 times
normal) is much higher than the level in thalassemia intermedia
(erythroid activity . 2 times normal) at the same hemoglobin
concentration (Fig 1A). This may either suggest that the
clearance of Epo is much faster in thalassemia than in marrow
failure, or alternatively that the renal production is to some
extent higher in the latter condition.
To establish any relationship between erythropoiesis and
sEpo, several investigators studied patients receiving myelosup-
pressive treatments. Overall, patients treated with chemother-
apy were found to have a temporary, but prominent, increase in
sEpo titers without a concomitant change in Hb concentra-
tion.10,11,27-30 However, different interpretations were provided
for the observed marked sEpo increase before the decrease in
Hb after treatment with cytostatic drugs. Possible explanations
included: (1) cytotoxic therapy causes direct injury to Epo-
producing cells in the kidney in a manner that mimics hypoxia;
(2) BM inhibition triggers an unknown stimulus for Epo
production; (3) a decreased mass of erythroid precursors
disrupts the usual Epo degradation pathway, reduced Epo use
resulting in prolonged sEpo lifespan and concentration; (4)
cytotoxic drugs enhance Epo mRNA stability with a consequent
increase in protein synthesis.
Our studies after myelosuppressive therapy (Figs 2 and 3)
definitely show an inverse relationship between erythroid
activity (as indicated by sTfR) and sEpo. Such relationship is
further reinforced by observations in patients with iron defi-
ciency, megaloblastic anemia, and PRCA (Figs 4 through 8).
Although it has been suggested that iron deprivation increases
Epo production,31 cobalamin deficieny does not raise Epo level
per se, but only to the extent that it produces anemia.32 It is not
clear why the erythroid marrow of our patient with PRCA did
not respond to endogenous Epo and responded to exogenous
rHuEpo (Fig 8). We cannot rule out that the erythroid response
was spontaneous and unrelated to rHuEpo, but at least three
other similar cases have been reported.18 Endogenous Epo
production might have been defective in this patient despite the
elevated sEpo levels if one assumes that these levels essentially
reflected a very low utilization rate by the few erythroid cells
existing in the BM.
Overall, our findings point to an inverse relationship between
red blood cell precursor mass and sEpo level: the higher the
number of red blood cell precursors, the lower the sEpo level.
There are four possible explanations for this relationship: (1)
sEpo levels are independently regulated by the rate of hormone
Fig 5. Time course of sEpo, reticulocyte count, and HFR in a
patient with iron deficiency anemia treated with IV iron saccharate
from day 0. HFR, ie, the most immature reticulocytes, expressed as %
of total reticulocytes.
Fig 6. Time course of Hb level, sEpo, and sTfR in a patient with
megaloblastic anemia due to vitamin B12 deficiency treated with
vitamin B12 (IM as cyanocobalamin, 500 mg per day). A marked
decrease in serum Epo was seen after the first injection and before
any increase in Hb level. There was a parallel increase in serum
transferrin receptor, indicating a rapid expansion of the erythroid
marrow during the first days of treatment.
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use by erythroid cells through Epo receptors; (2) erythroid
marrow hypoplasia triggers a stimulus for Epo synthesis; (3)
erythroid marrow expansion inhibits renal production; and (4)
Epo excretion by the kidneys is directly influenced by erythroid
activity.
Two reports argue against the model of regulation by the
utilization rate, Piroso et al33 studied Epo lifespan in rats with
hypoplastic and hyperplastic BMs. They found no significant
difference and concluded that it is unlikely that erythroid
activity determines sEpo lifespan and catabolism. Using a
mouse model, Lezo´n et al34 have found an inverse relationship
between the rate of stimulated Epo production and erythropoi-
etic marrow activity. They concluded that decreases in sEpo
levels during periods of rapidly increasing erythropoiesis are
the reflection of a decrease in the rate of production rather than
an increase in the rate of utilization by expanding erythroid
cells.
Although the above direct studies failed to show evidence for
increased utilization when the erythroid precursor mass is
expanded, a large body of evidence points to a role by the
utilization rate in the regulation of circulating levels of hemato-
poietic growth factors. In particular, thrombopoietin levels
appear to be primarily regulated through absorption and metabo-
lism by both megakaryocytes and platelets.35 Our findings
indicate that the rate of utilization by erythroid cells acts as an
independent determinant of sEpo, this latter being a balance
between the rate of renal production and the rate of erythroid
consumption. This interpretation may be too simplistic, as other
factors linking erythron to renal production likely exist. Indeed,
we have previously reported elevated sEpo levels in compen-
sated hereditary spherocytosis, a condition defined by decreased
red blood cell lifespan without anemia.36 Products of red blood
cell destruction may not only exert a distinct stimulatory effect
on BM,37,38 but also influence Epo production.
From a practical point of view, we have recently proposed
that treatment with rHuEpo should be started only after an
inadequate erythropoietin production has been documented, eg,
by showing sEpo levels , 100 mU/mL in patients with Hb
values , 10 g/dL.5 According to the present study, when using
sEpo for this purpose, it might be necessary to take into account
the patient’s erythroid activity. For example, patients with
erythroid hypoplasia may present sEpo values . 100 mU/mL
due to the small erythroid cell mass and still be responsive to
rHuEpo treatment.18 We are not suggesting the adoption of the
empirical correction for sEpo reported in Fig 1B, but consider-
ation of this point in the clinical reasoning of the patient-
oriented approach to the use of rHuEpo.5 In this reasoning, it
Fig 7. Time course of Hb level and sEpo (upper panel) and of sTfR,
reticulocyte count and HFR (lower panel) in a patient with megaloblas-
tic anemia due to folate deficiency treated with folic acid (15 mg per
day IM). A marked decrease in serum Epo was seen after the first
injection and before any increase in Hb level. There was a parallel
increase in HFR, sTfR, and reticulocyte count, indicating a rapid
expansion of the erythroid marrow during the first days of treatment.
Fig 8. Time course of Hb level, sEpo, and sTfR in a patient with
PRCA responding to treatment. The patient was given rHuEpo at an
initial dose of 150 U/kg per day SC, 5 days a week; dosage was
reduced to three weekly administrations when Hb level achieved 12
g/dL and treatment was discontinued after 8 weeks. Serum Epo
started to decrease as erythroid marrow activity reappeared, before
any change in Hb level.
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should be taken into account that apparently normal sEpo levels
in patients with hypoproliferative anemia may reflect an inad-
equate production combined with reduced utilization rate and,
conversely, that inappropriately low levels in patients with
proliferative anemia can be simply due to an accelerated
hormone consumption.
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